• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
California Health Advocates

California Health Advocates

  • Contact
  • Home
  • About Us
    • Contact
    • Our Team
    • Mission
    • Education Services
    • About HICAP
    • Press
    • Testimonials
  • MEDICARE COUNSELING
  • Fact Sheets
  • Topics
    • The Basics
    • Prescription Drugs
    • Low-Income Help
    • Medigap
    • Medicare Advantage
    • Other Health Insurance
    • Appeals
    • Billing & Claims
    • Disabilities
    • Long-Term Care
    • Tribal Nations & Medicare
    • Health Care Reform
    • Advocacy & Policy
    • Glossary
  • Fraud & Abuse
  • Medicare Complaints
  • Blog
  • Donate

Fraud Lawsuit Results in Mandated HUMIRA Marketing Reforms & $24 Million Payment by Drugmaker AbbVie

California Health Advocates > Fraud & Abuse > Fraud Lawsuit Results in Mandated HUMIRA Marketing Reforms & $24 Million Payment by Drugmaker AbbVie

Posted by Karen Joy Fletcher on August 6, 2020

Below is a press release from the California Department of Insurance detailing their lawsuit against drugmaker AbbVie and their fraudulent marketing practices of the blockbuster drug, HUMIRA. It also reports on the mandated marketing reforms and a $24 million payment to CDI and the whistleblower from AbbVie.

California Department of Insurance fraud lawsuit results in reforms of HUMIRA marketing and $24 million payment by drugmaker AbbVie

 

Insurance Commissioner Ricardo Lara today announced a settlement agreement with AbbVie Inc. to resolve a lawsuit alleging violations of the California Insurance Frauds Prevention Act (Act) involving the marketing of blockbuster prescription drug HUMIRA. AbbVie agreed to reform its HUMIRA marketing practices in California, including disclosing that registered nurses employed as “Ambassadors” to interact with patients about HUMIRA are actually paid by the company, not a medical provider, and reforming how HUMIRA is marketed to health care providers. In addition, as provided for in the Act, AbbVie has also paid a combined $24 million to the State of California and the whistleblower who brought the case to the Department’s attention.

 

“AbbVie’s prior practices in marketing HUMIRA egregiouslyput profits ahead of transparency in patient care and violated California law,” said Commissioner Lara. “This settlement delivers important reforms to AbbVie’s business practices and a substantial monetary recovery that will be used to continue to combat insurance fraud.”

 

In October 2016, the Department began an investigation into AbbVie after receiving a whistleblower case filed by a registered nurse who was employed as an AbbVie Ambassador in Florida. After its investigation, the Department intervened in that case and filed a Superseding Complaint alleging that AbbVie violated California’s Insurance Frauds Prevention Act. Among other things, the Department alleged that AbbVie violated the Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward HUMIRA prescriptions. The Department alleged that Nurse Ambassadors interfered with the flow of doctor-patient communications and did not directly answer questions pertaining to HUMIRA’s side effects. The Department also alleged that other HUMIRA marketing activities constituted kickbacks in violation of the Act, including, for example, the provision of meals and drinks to providers outside the context of speakers programs.

 

While AbbVie continues to deny the allegations, as a part of the settlement, AbbVie agreed to reforms, including:

 

  • Ambassadors will disclose to patients that they are provided by AbbVie and do not work under the direction of the patient’s health care provider.
  • The company will implement a policy modification prohibiting HUMIRA sales representatives from inviting HUMIRA prescribing health care providers to offsite business meals, except as part of the AbbVie speaker programs.
  • AbbVie will provide patients with the U.S. FDA-approved HUMIRA medication guide and Ambassadors will direct patients to the medication guide and their health care provider regarding side effects and safety risk.
  • The company will provide guidance and training that Ambassadors shall not have patient-specific discussions with providers who prescribe HUMIRA.
  • AbbVie employees will be prohibited from describing Ambassadors to health care providers as “extensions of their offices” and from providing to providers any contact information for Ambassadors who interact with HUMIRA patients.
  • AbbVie employees and Ambassadors will not actively participate in conversations between patients and insurance companies.

 

The complete list of AbbVie’s business practice reforms can be found in the settlement.

 

# # #

Media Notes:

    • The settlement agreement can be found here.
    • Insurance Frauds Preventions Act Allocation Agreement can be found here.
    • This lawsuit and resolution applies to the case filed in Alameda Superior Court (Case No. RG18893169) which alleges violations of the Insurance Fraud Prevention Act. There is a separate case pending (Suarez et al v. AbbVie, Inc.) in the Northern District of Illinois that alleges violations of the Federal False Claims Act and various state false claims acts. The Commissioner is not a party to that litigation.
    • The non-monetary terms discussed in this release only apply in California.

Filed Under: Fraud & Abuse, Latest News

Previous Post: « HEALS Act Would Hurt Rather than Help Older Adults
Next Post: You Can Now Sign Up for Medicare Part B Online, by Fax or Mail »

About Karen Joy Fletcher

Our blogger Karen Joy Fletcher is CHA's Communications Director. With a Masters in Public Health from UC Berkeley, she is the online "public face" of the organization, provides technical expertise, writing and research on Medicare and other health care issues. She is responsible for digital content creation, management of CHA’s editorial calendar, and managing all aspects of CHA’s social media presence. She loves being a "communicator" and enjoys networking and collaborating with the passionate people and agencies in the health advocacy field. See her current articles.

Related Posts

  • Fraud Alert – Scammers Steal Money Through Fake HHS Websites & Social Media Schemes
  • SMP Liaison Spotlight – Meet Steven Perez-Mejia!
  • Together Let’s Slam the Scam!
  • Save Medicare Act – Only Medicare is Medicare

Primary Sidebar

Change Text Size

  • 100%  110%  120%  130%  

News & Blog Categories

  • Medicare Advantage
  • Low-Income help
  • Medicare & Disabilities
  • Medicare Basics
  • Prescription Drugs
  • Medicare & Other Health Insurance
  • Medicare Billings, Claims & Appeals
  • Health Care Disparities
  • Fraud & Abuse

—

  • COVID-19
  • Resources
  • Health Care Reform
  • Long-Term Care
  • CHA News

—

  • Advocacy & Policy
  • Letters and Comments to Policymakers
  • Legislative and Congressional Testimony
  • Policy Briefs

Send Us Comment

Do you have comments or concerns about your Medicare coverage? Issues regarding getting your needed prescriptions from your Part D plan, or a Medicare Advantage plan representative's marketing practices? Let us know at comments@cahealthadvocates.org.

We are dedicated to making Medicare's program work well for all beneficiaries. Your feedback from your own or your client's concerns and experiences with Medicare, will guide our Medicare advocacy efforts with key policy and decision-makers in both California and nationally with the Centers for Medicare and Medicaid Services (CMS) and Congress.

Archives

Donate Today

Footer

Sign up for our newsletter

Choose the news you'd like to receive

Important Links

  • About Us
  • Fact Sheets
  • Blog
  • Donate
  • Contact
  • Privacy Notice
  • Cookie Policy
  • Accessibility Statement

Follow Us

Copyright © 2023 · California Health Advocates · Web Design by TWK Web and Print Design · Log in